ArticleJCO precision oncology2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Coupled SDE-ODE Modeling of Tumor-Immune Dynamics to Infer Biomarker Release.Bulletin of mathematical biology · 2026Article
- Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC.Medical sciences (Basel, Switzerland) · 2026Review
- Harmonising ctDNA Measurement in Haematological Malignancies: Traceability, Commutability and Reporting.Diagnostics (Basel, Switzerland) · 2026Review
- Integration of Nanotechnology with ctDNA: New Advances for Monitoring Neoadjuvant Chemotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeQuantifying changes in circulating tumor DNA (ctDNA) during treatment can rapidly identify patients responding to therapy, but accurate interpretation requires an understanding of variability in ctDNA levels in the absence of treatment. This analysis of 360 patients with advanced epidermal growth factor receptor (
methodsScreening and cycle 1, day 1 (C1D1) pretreatment samples from 132 previously untreated and 228 previously treated patients in the FLAURA and AURA3 trials, respectively, had ctDNA quantified using next-generation sequencing (Guardant360/GuardantOMNI NGS panel; mean variant allele frequency [VAF] or
resultsIn FLAURA and AURA3, ≥20% reductions in ctDNA levels (panel mean VAF) from screening to C1D1 occurred in 31/132 (23.5%) and 43/228 (18.9%) patients with paired pretreatment plasma samples, respectively, including ≥50% reductions in 12 (9.1%) and 23 (10.1%) patients, and 100% reductions (ctDNA clearance) in 0 and 5 (2.2%) patients. Background variability was not fully accounted for by intra-NGS or NGS-ddPCR technical variability or other potential sources of variability; larger changes were associated with low VAF and low cell-free DNA (cfDNA) input.
conclusionIntrapatient ctDNA variability over time in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.